Symbol="NRIX"
AssetType="Common Stock"
Name="Nurix TherapeuticsÂ Inc"
Description="Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California."
CIK="1549595"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, US"
FiscalYearEnd="November"
LatestQuarter="2023-02-28"
MarketCapitalization="455950000"
EBITDA="-179164992"
PERatio="None"
PEGRatio="None"
BookValue="5.78"
DividendPerShare="0"
DividendYield="0"
EPS="-3.49"
RevenuePerShareTTM="0.818"
ProfitMargin="0"
OperatingMarginTTM="-4.415"
ReturnOnAssetsTTM="-0.285"
ReturnOnEquityTTM="-0.616"
RevenueTTM="41691000"
GrossProfitTTM="-145870000"
DilutedEPSTTM="-3.49"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.318"
AnalystTargetPrice="28.27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="14.31"
PriceToBookRatio="1.701"
EVToRevenue="6.41"
EVToEBITDA="-1.536"
Beta="1.625"
num_52WeekHigh="19.91"
num_52WeekLow="8.34"
num_50DayMovingAverage="10.15"
num_200DayMovingAverage="10.94"
SharesOutstanding="47445400"
DividendDate="None"
ExDividendDate="None"
symbol="NRIX"
open="9.84"
high="10.19"
low="9.51"
price="9.98"
volume="288061.00"
latest_trading_day="2023-07-12"
previous_close="9.61"
change="0.37"
change_percent="3.8502%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="41"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="59"
Volume_recent_avg="349386"
Change_recent_avg="-0.02"
Delta_recent_avg="0.63"
Variance_recent_avg="0.32"
Change_ratio_recent_avg="-0.29"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="TRUE"
Aroon_momentum_positive="59"
Aroon_momentum_negative="41"
image_negative_thumbnail_id_1="101"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0075.jpeg"
image_negative_thumbnail_id_2="1107"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0140.jpeg"
image_neutral_thumbnail_id_1="598"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_neutral_thumbnail_id_2="576"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0023.jpeg"
image_positive_thumbnail_id_1="646"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0062.jpeg"
image_positive_thumbnail_id_2="644"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0064.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
